TEVETEN PLUS TABLET

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

EPROSARTAN (EPROSARTAN MESYLATE); HYDROCHLOROTHIAZIDE

Доступна с:

BGP PHARMA ULC

код АТС:

C09DA02

ИНН (Международная Имя):

EPROSARTAN AND DIURETICS

дозировка:

600MG; 12.5MG

Фармацевтическая форма:

TABLET

состав:

EPROSARTAN (EPROSARTAN MESYLATE) 600MG; HYDROCHLOROTHIAZIDE 12.5MG

Администрация маршрут:

ORAL

Штук в упаковке:

7/28

Тип рецепта:

Prescription

Терапевтические области:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Обзор продуктов:

Active ingredient group (AIG) number: 0250121001; AHFS:

Статус Авторизация:

CANCELLED POST MARKET

Дата Авторизация:

2023-09-18

Характеристики продукта

_ _
_ _
_TEVETEN_
_®_
_ PLUS, eprosartan mesylate / hydrochlorothiazide Product Monograph _
_Page 1 of 47_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
TEVETEN® PLUS
eprosartan mesylate / hydrochlorothiazide
Tablets, 600 mg eprosartan / 12.5 mg hydrochlorothiazide, Oral
Angiotensin II Receptor (AT1) Antagonist and Diuretic
BGP Pharma ULC
85 Advance Road
Etobicoke, Ontario
M8Z 2S6
Date of Initial Authorization:
JUN 08, 2004
Date of Revision:
SEP 26, 2022
Submission Control Number: 263867
_ _
_ _
_ _
_TEVETEN_
_®_
_ PLUS, eprosartan mesylate / hydrochlorothiazide Product Monograph _
_Page 2 of 47_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism
07/2020
7 WARNINGS AND PRECAUTIONS, Ophthalmologic
02/2021
7 WARNINGS AND PRECAUTIONS, Respiratory
09/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.1
Dosing Considerations
............................